Illinois General Assembly - Bill Status for HB3493
Illinois General Assembly

  Bills & Resolutions  
  Compiled Statutes  
  Public Acts  
  Legislative Reports  
  IL Constitution  
  Legislative Guide  
  Legislative Glossary  

 Search By Number
 (example: HB0001)
Search Tips

Search By Keyword

 Bill Status of HB3493  102nd General Assembly


Short Description:  PRESCRIPTION DRUG-AFFORD

House Sponsors
Rep. Will Guzzardi - Mary E. Flowers - Karina Villa - Yehiel M. Kalish, Thaddeus Jones, Fred Crespo, Robert Rita, Jaime M. Andrade, Jr., Terra Costa Howard, Michael J. Zalewski, Deb Conroy, Theresa Mah, Kelly M. Cassidy, Delia C. Ramirez, Jonathan "Yoni" Pizer, Elizabeth Hernandez, Lindsey LaPointe, Michelle Mussman, Michael Halpin, Nicholas K. Smith, Jonathan Carroll, John Connor, Maurice A. West, II, Daniel Didech and Debbie Meyers-Martin

Last Action
DateChamber Action
  3/4/2020HouseTabled Pursuant to Rule 22(g)

Statutes Amended In Order of Appearance
New Act
30 ILCS 105/5.891 new


Synopsis As Introduced
Creates the Prescription Drug Affordability Act. Defines terms. Creates the Prescription Drug Affordability Board and includes provisions regarding: purpose; members; alternate members; conflict of interest; terms; additional staff; salary; compensation and reimbursement; and meetings. Creates the Prescription Drug Affordability Stakeholder Council and includes provisions regarding: purpose; members; knowledge requirements; terms; and compensation. Provides the manner in which a conflict of interest shall be disclosed. Provides that gifts or donations of services or property that indicate a potential conflict of interest may not be accepted by any member of the Board, Board staff, or third-party contractor. Includes provisions on applicability. Provides that the Board shall identify specified prescription drug products and determine whether each prescription drug product should be subject to a cost review. Provides that if the Board finds that spending on a prescription drug product creates affordability challenges, the Board shall establish an upper payment limit that applies to all purchases and payor reimbursements. Includes provisions regarding remedies and an appeal process. Creates the Prescription Drug Affordability Fund. Provides that the Board shall submit a report to the General Assembly including specified information. Includes a provision on term expiration for Board and Council members. Provides that the Board shall conduct a study of the operation of the generic drug market that includes specified information on or before June 1, 2020. Makes conforming changes in the State Finance Act. Effective immediately.

House Committee Amendment No. 1
Deletes reference to:
30 ILCS 105/5.891 new
Adds reference to:
30 ILCS 105/5.930 new

Replaces everything after the enacting clause. Reinserts the provisions of the introduced bill creating the Prescription Drug Affordability Act, and makes changes. Modifies provisions concerning the membership and powers of the Prescription Drug Affordability Board. Modifies provisions concerning the membership of the Prescription Drug Affordability Stakeholder Council. Specifies requirements concerning drug cost affordability review. Provides additional duties power and duties for the Attorney General concerning remedies under the Act. Provides additional Board reporting requirements under the Act. Provides requirements concerning Employee Retirement Income Security Act (ERISA) plans and Medicare Part D plans. Provides findings provisions. Makes other changes. Effective January 1, 2021.

Actions 
DateChamber Action
  2/15/2019HouseFiled with the Clerk by Rep. Will Guzzardi
  2/15/2019HouseFirst Reading
  2/15/2019HouseReferred to Rules Committee
  3/1/2019HouseAdded Chief Co-Sponsor Rep. Mary E. Flowers
  3/5/2019HouseAssigned to Prescription Drug Affordability & Accessibility Committee
  3/6/2019HouseAdded Co-Sponsor Rep. Thaddeus Jones
  3/27/2019HouseMotion Do Pass - Lost Prescription Drug Affordability & Accessibility Committee; 008-008-000
  3/27/2019HouseRemains in Prescription Drug Affordability & Accessibility Committee
  3/29/2019HouseRule 19(a) / Re-referred to Rules Committee
  3/29/2019HouseAdded Chief Co-Sponsor Rep. Karina Villa
  4/2/2019HouseAdded Co-Sponsor Rep. Fred Crespo
  4/11/2019HouseAdded Co-Sponsor Rep. Robert Rita
  4/18/2019HouseAdded Co-Sponsor Rep. Jaime M. Andrade, Jr.
  5/30/2019HouseAdded Co-Sponsor Rep. Terra Costa Howard
  2/4/2020HouseAssigned to Prescription Drug Affordability & Accessibility Committee
  2/18/2020HouseAdded Co-Sponsor Rep. Yehiel M. Kalish
  2/20/2020HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Will Guzzardi
  2/20/2020HouseHouse Committee Amendment No. 1 Referred to Rules Committee
  2/20/2020HouseAdded Co-Sponsor Rep. Michael J. Zalewski
  2/20/2020HouseAdded Co-Sponsor Rep. Deb Conroy
  2/25/2020HouseHouse Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee
  2/26/2020HouseAdded Co-Sponsor Rep. Theresa Mah
  2/26/2020HouseAdded Co-Sponsor Rep. Kelly M. Cassidy
  2/26/2020HouseRemoved Co-Sponsor Rep. Yehiel M. Kalish
  2/26/2020HouseAdded Chief Co-Sponsor Rep. Yehiel M. Kalish
  2/26/2020HouseAdded Co-Sponsor Rep. Delia C. Ramirez
  2/26/2020HouseAdded Co-Sponsor Rep. Jonathan "Yoni" Pizer
  2/27/2020HouseAdded Co-Sponsor Rep. Elizabeth Hernandez
  2/28/2020HouseAdded Co-Sponsor Rep. Lindsey LaPointe
  3/2/2020HouseAdded Co-Sponsor Rep. Michelle Mussman
  3/3/2020HouseAdded Co-Sponsor Rep. Michael Halpin
  3/3/2020HouseAdded Co-Sponsor Rep. Nicholas K. Smith
  3/3/2020HouseAdded Co-Sponsor Rep. Jonathan Carroll
  3/3/2020HouseAdded Co-Sponsor Rep. John Connor
  3/3/2020HouseAdded Co-Sponsor Rep. Maurice A. West, II
  3/3/2020HouseAdded Co-Sponsor Rep. Daniel Didech
  3/3/2020HouseAdded Co-Sponsor Rep. Debbie Meyers-Martin
  3/4/2020HouseHouse Committee Amendment No. 1 Adopted in Prescription Drug Affordability & Accessibility Committee; by Voice Vote
  3/4/2020HouseMotion Do Pass as Amended - Lost Prescription Drug Affordability & Accessibility Committee; 008-005-001
  3/4/2020HouseTabled Pursuant to Rule 22(g)

Back To Top